KEY DETAILS
Boehringer and Zealand Pharma's survodutide, which helped diabetes patients lose up to 13.1% of their weight in results released October 1, is seen as disappointing.
Lilly's EloraTZP trial data, released September 30, is adding competitive pressure on rival Novo Nordisk.
Federal prosecutors announced on September 29 that two people were charged in a scheme to sell counterfeit Ozempic.
Regeneron's Phase 2 COURAGE trial found trevogrumab cut semaglutide-related lean mass loss and preserved about 70% of thigh muscle in an MRI substudy.
Ten drugmakers joined a federal pilot that lets them pay 340B discounts as rebates instead of upfront, a change hospitals oppose. No GLP-1 drugs are on the list.
Boehringer and Zealand Pharma's survodutide helped diabetes patients lose up to 13.1% of their weight in trial results released October 1, a figure that lands below what rivals have posted. Ten drugmakers also joined a federal 340B rebate pilot, while Lilly's EloraTZP data, released September 30, added pressure on Novo Nordisk. Federal prosecutors announced charges on September 29 against two people over counterfeit Ozempic, and a new study pointed to a possible fix for one of GLP-1 therapy's persistent side effects: muscle loss.
The 13.1% figure for Boehringer and Zealand Pharma's drug came from patients with diabetes, and it sits below what the leading obesity treatments have already shown in similar trials. That gap matters because the obesity drug market has grown crowded, and a new treatment needs a clear edge to stand out once it reaches pharmacies. Separately, ten drugmakers joined a federal pilot that lets them pay 340B discounts as rebates instead of upfront, a change hospitals oppose. No GLP-1 drugs are on the list.
That bar is only getting higher. Lilly's EloraTZP trial data, released September 30, added to the competitive pressure Novo Nordisk is already facing, as Lilly extends its lead in the obesity drug market. For Novo, the timing is not ideal, coming as attention has already turned toward which company can deliver the strongest results with the fewest tradeoffs. Patients and doctors watching this competition stand to benefit if it pushes companies toward drugs with better results and fewer downsides.
Competition among legitimate drugmakers is one story. But as demand for these medications has grown, so has the market for counterfeit versions, and on September 29 federal prosecutors announced charges against two people in a scheme to sell counterfeit Ozempic. The charges are a reminder that patients should get these medications through verified pharmacies and legitimate prescriptions, since the ingredients and dosing in counterfeit products are not guaranteed. Anyone who suspects they have received a counterfeit product should raise it with their pharmacist or doctor right away.
On the research side, a new study offered more encouraging news for patients on legitimate GLP-1 therapy. Researchers found that trevogrumab cut the lean mass loss associated with semaglutide roughly in half, addressing a concern many patients raise about these drugs: that some of the weight lost comes from muscle rather than fat. That distinction matters because lean mass supports strength and metabolic health, and losing too much of it can offset some of the benefits of weight loss. The finding suggests that pairing GLP-1 therapy with a drug like trevogrumab could change how doctors approach long term treatment.
That finding comes from Regeneron's Phase 2 COURAGE trial, which also found that trevogrumab preserved about 70% of thigh muscle in an MRI substudy. The results give doctors a clearer picture of how trevogrumab performs alongside these drugs. If the results hold up in larger trials, they could support a treatment approach that preserves muscle while patients still lose fat. That would address one of the more common tradeoffs patients and doctors have raised about GLP-1 therapy since it became widely used.
Readers weighing options in obesity treatment may want to keep an eye on the trevogrumab research, since muscle preservation has become one of the more important questions in long term GLP-1 use. The counterfeit Ozempic charges are also a good prompt to confirm that any prescription comes from a licensed pharmacy rather than an unverified seller. Before acting on any of today's developments, talk with your doctor about whether they change anything about your own treatment plan.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.